The role of indoxyl sulfate in the increased incidence of thrombosis formation in chronic kidney disease by Alousi, Faisal Fahd
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
The role of indoxyl sulfate in the
increased incidence of thrombosis
formation in chronic kidney disease
https://hdl.handle.net/2144/26653
Boston University
   
BOSTON UNIVERSITY 
 












THE ROLE OF INDOXYL SULFATE IN THE INCREASED INCIDENCE OF 




















Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2017  






































  © 2017 by 
  FAISAL ALOUSI 
  All rights reserved  






First Reader   
 Mostafa Belghasem, M.D., Ph.D. 
 Instructor of Pathology and Laboratory Medicine 
 
 
Second Reader   
 Gwynneth Offner, Ph.D. 
 Associate Professor of Medicine
  iv 
ACKNOWLEDGMENTS 
 
I would like to thank my Adviser, Dr. Offner and my Mentor, Dr. Mostafa 
Belghasem.  
 
    
  v 
THE ROLE OF INDOXYL SULFATE IN THE INCREASED INCIDENCE OF 
THROMBUS FORMATION IN CHRONIC KIDNEY DISEASE 
FAISAL ALOUSI 
ABSTRACT 
The increased risk of atherothrombosis in chronic kidney disease (CKD) has been 
under extensive examination for decades now. However, a treatment tailored for CKD 
patients is yet to be found. Current management plans can only tackle comorbidities and 
mostly fail. This thesis study examines the current literature related to CKD and 
thrombosis. The aim is to find a target suitable for therapeutic exploration. Normalizing 
the risk of thrombosis in CKD patients could curb a huge margin of their morbidity and 
mortality. 
In recent years, molecular biology studies attributed the extreme thrombogenicity 
in CKD to the retained uremic toxins. Indolic compounds are uremic toxins with a well 
described point of thrombotic activation. Of them, indoxyl sulfate is to be highlighted 
since it was shown to that it is one of the strongest pro-thrombotic uremic toxin. It is 
possible to therapeutically target this CKD specific cause of hyperthrombogenicity.  
Further research is very much needed in this area.  
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 Chronic kidney disease (CKD) is a major health problem around the 
world. Its prevalence is increasing in the United States (U.S) even beyond 15 million 
patients (1). In 1973, CKD patients progressing to end stage renal disease (ESRD) were 
10,000 under governmental health care. That number increased to 547,982 in 2008. In 
that year, It is documented that the financial burden of ESRD alone reached $39.5 billion 
(2).  
 
One of the key morbidity and mortality components in CKD is the increased 
incidence of atherothrombosis. Now, it is established that CKD is a risk factor for the 
occurrence of hemostatic disorders and the increased prevalence of cardiovascular 
disease (CVD). Traditional cardiovascular risk factors are insufficient to explain the high 
coincidence of CVD among CKD patients, suggesting the existence of “missing links” 
connecting cardiovascular system and kidney (3, 4).   
 
In this thesis, the subject at hand is going to be elaborated from a renal 
perspective. It is going to be approached from the basics, starting from the kidneys and 
their functions in brief. Then CKD will be specifically addressed since the metabolic 
impact of the toxin, indoxyl sulfate, requires long standing exposure. After that, 
thrombosis with it clotting cascade will be mentioned along with the other different 
causes of increased risk in CKD. Lastly, indoxyl sulfate will be discussed as a naturally 
occurring metabolite that can reach toxic levels due to renal insufficiency. 
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KIDNEY 
The kidney is the major contributor to the maintenance of homeostasis in the 
body. Physiologically, it achieves homeostasis by controlling water and minerals retained 
in the blood and expelling metabolic wastes.  It is about 10 cm long in humans. 
Developmentally, a pair of kidneys is located below the diaphragm and behind the 
peritoneum. The entire blood volume is filtered every 45 minutes. Maintenance of 
homeostasis directly affects the amount of the excreted water volume. Each kidney has 
around 1 million nephrons, the basic structural and functional unit of the kidney. It has 2 
main components: glomerulus and attached renal tubule. The direction blood flow is 
afferent arteriole, glomerular capillaries, efferent arteriole, vasa recta (the capillaries 
surrounding the tubules), renal venules then back into the circulatory system.   
 
The major functions of the kidneys are waste excretion, electrolyte balance, 
hormonal synthesis, blood pressure regulation and glucose hemostasis. Waste excretion is 
done through glomerular filtration, tubular secretion and tubular catabolism.  Glomerular 
filtration is for excretion of nitrogenous products of protein metabolism. Tubular 
secretion covers excretion of organic acids and organic bases. Tubular catabolism ensures 
degradation and excretion of medications and hormonal peptides. Electrolyte balance is 
essential to control water volume status, osmolar balance and acid-base balance. Some 
minerals are essential for cell function and the kidneys also control the blood levels of 
these compounds. Electrolyte balance is maintained through tubular sodium chloride 
reabsorption, tubular potassium and hydrogen   secretion, bicarbonate synthesis   and 
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reabsorption and lastly tubular calcium, magnesium and phosphate transport.  For the 
hormonal functions, erythropoietin is produced to increase red blood cell production in 
the bone marrow and renin is produced to alter vascular resistance and increase 
aldosterone secretion. In relation to hormonal cycles, vitamin D activation for calcium 
homeostasis is done in the kidney. Blood pressure regulation is achieved by sodium 
excretion and renin production. . Glucose homeostasis involves synthesis of  glucose 
from lactate, pyruvate and amino acids in a process called gluconeogenesis in prolonged 
starvation. 
 
GLOMERULAR FILTRATION RATE (GFR) 
The glomerular filtration rate is a measure of the fluid the glomeruli in both 
kidneys filter in a given amount of time. It is used to follow  the progression or remission 
of renal impairment. Per day, 180 liters (L) are filtered; most of this filtrate is reabsorbed 
immediately. What is excreted accounts  for 1.0L to 1.5L of urine output daily.  
Normally, the adult output of urine is more than 0.5mL per kilogram per hour. Aging 
affects GFR negatively and this parameter begins to deteriorate after young adulthood. 
The status of kidney or renal function is measured with GFR (5). In linical 
practice, GFR is derived from the level of creatinine serum concentration,  a byproduct 
from muscular energy metabolism. Creatinine is not reabsorbed after filtration. This 
makes it a good biomarker for filtration even though it is excreted to some degree 
through tubular secretion.  
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PATHOLOGY OF KIDNEYS 
There are many ways to divide and categorize renal pathologies. However, this 
thesis considers the topic in relation to the function of maintaining homeostasis. For that, 
the environment is impacted more when the pathology is evaluated over time. . 
Beginning from acute renal disease, it is rapid, short acting and most of the time self-
limiting. It can be a result of critical illness, circulatory shock, burns, trauma, nephrotoxic 
drugs, radiocontrast agents and poisons. On the other hand, chronic kidney disease is a 
long-standing condition, which alters the regular functions of the entire body due to 
continuous failure to reach homeostasis references. 
 
CHRONIC KIDNEY DISEASE (CKD) 
CKD is characterized by an irreversibly progressive loss of renal function. 
According to Kidney Disease Outcomes Quality Initiative (KDOQI) and the Kidney 
Disease Improving Global Outcomes (KDIGO), CKD is defined as abnormalities of 
kidney structure or function, present for more than 3 months, with implications for health 
(6).  
The definition was elaborated in specific terms by the guild-line. The diagnosis is 
established when there is decrease in function by measuring GFR to be less than 60 mL 
per minute for more than a 3 month period. Pathologies are either structural, diagnosed 
by histopathological or radiological studies or functional, diagnosed by markers such as 
increased albumin urea. General signs of CKD include volume overload and hypertension 
with electrolyte and acid-base balance disorders and uremia (6). 
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Table 1. Prognosis of CKD by GFR and Albuminuria Categories: KDIGO 2012 (6). 
 




Staging of CKD requires three elements. In addition to asserting the risk from the 
functional status using the table, determining cause of disease is the third and most 
important element. This staging is used to set therapeutic plans and keep an eye for the 
complications expected at each stage of CKD. Unfortunately, in the majority of cases, 
effective treatment options are not available to regain function and cure the triggering 
source of the disease pathophysiology. Over all, hypertension, diabetes mellitus and 
cardiovascular disease are the major causes of CKD (3). 
   
CKD is a very complex, multifaceted diseasewith many systemic manifestations 
that are yet to be fully understood. However, there are some well-defined complications 
based on the known functions of the kidney. Anemia is seen due to low heamopoitin- 
what is this? leading to lower red blood cell count. Red cell survival is reduced in renal 
failure. Increased red cell destruction may occur during hemodialysis owing to 
mechanical, oxidant and thermal damage (7).   For bones, mineral disorders are quite 
common. In addition to lack of VitD activation for bone mineralization, osteoporosis is 
commonly found in CKD (8). 
 
Gastrointestinal complications can be also seen. These include decreased gastric 
emptying and increased esophageal reflux, peptic ulceration, acute pancreatitis and 
constipation, particularly in patients on peritoneal dialysis (9, 10). Hormonal changes are 
also seen leading to endocrine abnormalities such as hyperprolactinemia, which may 
present with galactorrhoea in men as well as women. Increased luteinizing hormone (LH) 
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levels in both sexes, and abnormal pulsatility of LH release. Decreased serum 
testosterone levels (only seldom below the normal level). Erectile dysfunction and 
decreased spermatogenesis are common. Absence of normal cyclical changes in female 
sex hormones is also commonly reported resulting  in oligomenorrhoea or total 
amenorrhoea (11). 
 
The high concentration or retention of metabolic wastes causes many changes in 
the normal cycle of essential metabolism due to the inherent negative feed back in most 
of these cycles. The clear example is urate retention that manifests into gout disease, 
which is a common feature of CKD (12). Another major example is insulin. It is normally 
catabolized by and to some extent excreted via the kidneys. For this reason, insulin 
requirements in diabetic patients decrease as renal failure progresses. By contrast, end-
organ resistance to insulin is a feature of advanced renal impairment resulting in 
modestly impaired glucose tolerance when a standard glucose tolerance test is carried 
out. Insulin resistance may contribute to hypertension and lipid abnormalities (13). These 
lipid abnormalities are further complicated by impaired clearance of triglyceride-rich 
particles and hypercholesterolemia (particularly in advanced renal failure) (14).  
 
Nervous system complications are many and for better elaboration, can be divided 
into central, peripheral and autonomic complications. For central nervous system, severe 
uremia causes an unusual combination of depressed cerebral function and decreased 
seizure threshold. Tremor and myoclonus are also features of severe uremia. Psychiatric 
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problems are also common. Patients can have anxiety, depression, phobias and psychoses 
with the progression of CKD. For autonomic nervous system complications, increased 
circulating catecholamine levels with renal impairment associated with down-regulation 
of α-receptors, impaired baroreceptor sensitivity and impaired efferent vagal function. 
For peripheral nervous system, median nerve compression in the carpal tunnel is common 
mostly due to musculoskeletal tone and firmness deterioration (15). 
 
Cardio vascular disease (CVD) burden is often seen in patients with CKD and is 
the major cause of morbidity and mortality in this population (16). CVD has many 
important manifestations including accelerated atherosclerosis, thrombosis, 
cardiomyopathy, resistant hypertension, frequent flash pulmonary edema and congestive 
heart failure, acute coronary syndrome and myocardial infarction. It is true that almost all 
CKD patients have other known risk factors for CVD; however, many studies have 
shown that CKD throughout its stages is an independent risk factor for almost all 
detrimental cardiovascular manifestations (17-20).   Furthermore, patients with CKD are 
8-10 fold at higher risk of death from the interventions and surgeries performed for the 
cardiovascular disease (21). This entire cohort of complications makes CKD one of the 
most potent and irreversible risk factors for CVD.  
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THROMBOSIS IN CKD 
The connection between CKD and thrombosis has many suggested theories with 
supportive observations. They include anemia, elevated levels of certain cytokines, 
increased calcium intake, abnormalities in bone mineral metabolism and lastly retention 
of uremic toxins (4, 22, . Of the uremic toxins, indoxyl sulfate (IS) is to be focused on. It 
is a metabolite of tryptophan retained at toxic levels in cases of CKD.. This CKD 
associated toxin is proposed to be a pro-thrombotic mediator, indirectly affecting the 
coagulation cascade from its triggering point, which is tissue factor (24). Tissue factor is 
a membrane protein that functions as a starting point for the extrinsic pathway of 
coagulation cascade. It is mainly expressed in sub-endothelial tissue. To sustain its level 
of expression while being continually degraded through ubiquitination, it requires 
stabilization from aryl hydrocarbon receptor (AHR). AHR is the intermediate which is 








Figure 1. Coagulation cascade through its intrinsic and extrinsic pathways. Tissue factor is 
indicated to be released upon tissue injury. It activates factor X by forming a complex with factor 
VII. Activated factor X then interacts with the surrounding tissue and platelets and push the 






Figure 2. Tryptophan metabolism with the harmful effects of some of it’s metabolites, 
including indoxyle sulfate (28). 
  
 12 
IS is a metabolite made by the liver from the indole ring that results from breaking 
down the essential amino acid tryptophan by gut floral bacteria. Normally, IS is mostly 
albumin-bound in circulation and is excreted via the kidney through the organic anion 
transporter (OAT) (29). In patients with CKD, it is documented that retained IS increases 
with the progression of the disease through its stages as shown in Table 2 (30, 31).  
With the increase in serum IS with CKD, the activation effect on AHR increases, 
which subsequently leads to more stabilized TF expressed on the membrane of sub-
endothelial tissue.(32) Plus, IS is also indicated to have an inhibitory effect on the 
proliferation of endothelial cells (33). 
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Table 2. Serum IS at each stage of CKD 
Stage of CKD GFR (ml/minute) Average IS (μg/ml) 
Normal >90 0.243 
Stage I >90 0.243 
Stage II 60–89 0.5 
Stage III 30–59 3.2 
Stage IV 15–29 5.4 
Stage V <15 19.8 
ESRD <15HD 42.5 
 











Potentiating clot formation by increasing tissue factor expression below the 
endothelial barrier puts CKD patients in a dangerous position since treatment involves 
many necessary invasive interventions. Also, it draws the attention to how virulent any 
thrombus formation can be after atherosclerotic injury. There are several options for 
therapeutic targets. AHR, the TF stabilizer (26, 34), already has blockers which have 
been identified in stud related to cancer and stem cells (35, 36). However, this molecule 
is involved in too many biological functions to be targeted in CKD, where almost all 
biological functions are suboptimal. This leads to another option, which is to target the 
over expressed TF by increasing ubiquitination.  
 
To probe into this, it is essential to have a proper assay and testing models. 
Biological assays are well defined, where cultured cells are needed to abundantly express 
AHR, for example hepatocytes (37), and TF, like in vascular smooth muscle cells 
(vSMC) (26). For animal models on the other hand, investigators have yet to agree on a 
CKD model with isolated retention of indoxyl sulfate leading to over-activation of TF. In 
theory, the OAT channel, the renal secretion route of IS, can be blocked for retention. 
Hopefully, a dose-response observation can be made with the degree of OAT channel 
blockage and TF expression. As an option, rodents express OAT channels for renal 
secretion (38). This can surely lead to a successful artificial potentiation of thrombosis 
specifically similar to CKD patients. The model can be used for many bleeding and 
clotting studies with ligands that passed the cell culture studies with increased TF 
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degradation.  The therapeutic target at hand may not prevent thrombosis, but the present 
extreme risk of progressive disease definitely worth investigating.  
 
CONCLUSION: 
The hyperthrombogenicity observed in CKD patients is a serious problem and yet 
to have an effectively manageable target. One of the key players in this phenomenon is 
believed to be the toxically retained IS. Since it is linked to potentiating clot formation 
through activation of TF, it is a promising avenue to explore therapeutically. This can 
lead to normalization of CKD related risk for thrombosis. The current literature 
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